A well-characterized mouse model of SSc involves daily subcutaneous injections of the antitumor antibiotic bleomycin (BLM), which leads to localized dermal fibrosis as well as pulmonary fibrosis. We have termed this the Systemic Bleomycin Model to distinguish it from the already-established Intratracheal (IT) model. We utilize this model, which mimics several key features of human SSc, to examine the pathological mechanisms underlying the development and progression of fibrosis in SSc. SOURCE: Ron Ammar (ron.ammar@bms.com) -  Bristol-Myers Squibb

Pluto Bioinformatics

GSE132869: A murine systemic bleomycin model of scleroderma